RESUMO
Hypertriglyceridemia is common in antiretroviral therapy-treated patients and Omega 3 fatty acids are being used as a intervention in reducing serum triglycerides (TG) in these patients. The objective of this study is to evaluate the effectiveness of the use of Omega 3 in the treatment of hypertriglyceridemia in HIV/AIDS patients on antiretroviral therapy. This study is a systematic review with meta-analysis of randomized clinical trials. Electronic databases - PubMed, Cochrane and Lilacs were researched. Fifty one articles were encountered. Nine were added to the meta-analysis. The reduction of triglycerides level was -77.55 mg (IC of -121.85 to -33.25) in Omega 3 groups. The analysis considering trials with more than 1000 mg of EPA/DHA included seven studies and the heterogeneity dropped to 0%.The reduction of combined averages was -101.56mg (IC of -145.76 to -57.37). The analysis considering trials with patients that had more than 200 mg/dL of initial triglycerides included also seven trials and the heterogeneity dropped to 0%. The reduction of combined averages was -114.15 mg (IC of -162.34 to -65.97). EPA/DHA supplementation reduces serum triglycerides levels in patients with HIV/AIDS-associated hypertriglyceridemia in stable use of antiretroviral therapy.
Assuntos
Fármacos Anti-HIV/efeitos adversos , Ácidos Graxos Ômega-3/uso terapêutico , Hipertrigliceridemia/tratamento farmacológico , Síndrome da Imunodeficiência Adquirida/complicações , Síndrome da Imunodeficiência Adquirida/tratamento farmacológico , Fármacos Anti-HIV/uso terapêutico , Infecções por HIV/complicações , Infecções por HIV/tratamento farmacológico , Humanos , Hipertrigliceridemia/etiologia , Ensaios Clínicos Controlados Aleatórios como Assunto , Triglicerídeos/sangueRESUMO
Abstract Hypertriglyceridemia is common in antiretroviral therapy-treated patients and Omega 3 fatty acids are being used as a intervention in reducing serum triglycerides (TG) in these patients. The objective of this study is to evaluate the effectiveness of the use of Omega 3 in the treatment of hypertriglyceridemia in HIV/AIDS patients on antiretroviral therapy. This study is a systematic review with meta-analysis of randomized clinical trials. Electronic databases - PubMed, Cochrane and Lilacs were researched. Fifty one articles were encountered. Nine were added to the meta-analysis. The reduction of triglycerides level was -77.55 mg (IC of -121.85 to -33.25) in Omega 3 groups. The analysis considering trials with more than 1000 mg of EPA/DHA included seven studies and the heterogeneity dropped to 0%.The reduction of combined averages was -101.56mg (IC of -145.76 to -57.37). The analysis considering trials with patients that had more than 200 mg/dL of initial triglycerides included also seven trials and the heterogeneity dropped to 0%. The reduction of combined averages was -114.15 mg (IC of -162.34 to -65.97). EPA/DHA supplementation reduces serum triglycerides levels in patients with HIV/AIDS-associated hypertriglyceridemia in stable use of antiretroviral therapy.
Resumo A hipertrigliceridemia é comum em pacientes tratados com terapia antirretroviral e os ácidos graxos ômega 3 estão sendo usados como uma intervenção na redução triglicérides séricos (TG) nesses pacientes. O objetivo deste estudo é avaliar a eficácia do uso do ômega 3 no tratamento da hipertrigliceridemia em pacientes com HIV/Aids em terapia antirretroviral. Este estudo é uma revisão sistemática com metanálise de ensaios clínicos randomizados. As bases de dados eletrônicas - PubMed, Cochrane e Lilacs foram pesquisadas. Cinquenta e um artigos foram encontrados. Nove incluídos na metanálise. A redução do nível de triglicerídios foi -77.55 mg (IC de -121,85 a - 33,25) no grupo com Omega 3. A análise considerando ensaios com mais de 1000 mg de EPA/DHA incluiu sete estudos e a heterogeneidade caiu para 0%. A redução das médias combinada foi -101.56 mg (IC de -145,76 a -57,37). A análise considerando ensaios com doentes que tinham mais do que 200 mg/dL, de triglicéridos iniciais incluiu também sete ensaios e a heterogeneidade caiu para 0%. A redução das médias combinada foi -114.15 mg (IC de -162,34 a -65,97). A suplementação de EPA/DHA reduz níveis de triglicérides séricos em pacientes com hipertrigliceridemia associada ao HIV/AIDS em uso de terapia antirretroviral estável.